Literature DB >> 28778255

Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry.

Michał Mazurek1, Eduard Shantsila2, Deirdre A Lane2, Andreas Wolff3, Marco Proietti2, Gregory Y H Lip4.   

Abstract

OBJECTIVE: To assess the influence of guideline-adherent vs nonadherent antithrombotic treatment (ATT) on stroke and mortality rates in an atrial fibrillation (AF) primary care population. PATIENTS AND METHODS: We used the Darlington Registry cohort, which included 105,000 patients from March 31, 2012, through March 31, 2013. Guideline adherence in ATT was assessed against 2014 National Institute for Health and Care Excellence guidelines, which recommend oral anticoagulation for stroke prevention as a default management unless a truly low risk of stroke (CHA2DS2-VASc=0 in men and 1 in women) is evident.
RESULTS: Of 2259 patients with AF (2.15%), 36.1% were undertreated, 50.8% were guideline adherent, and 13.1% were overtreated. Oral anticoagulation was declined by 5.0% and contraindicated in 8.3%. Of 67 incident strokes (3.0%), 66 (98.5%) occurred in high-risk patients (CHA2DS2-VASc ≥2). For the high-risk cohort, 1-year stroke rates were 4.5% (95% CI, 3.2%-6.3%) for undertreatment, 1.9% (95% CI, 1.2%-2.9%) for guideline adherence, and 7.2% (95% CI, 4.4%-11.6%) for overtreatment; corresponding mortality rates were 16.1% (95% CI, 13.6%-19.0%), 8.0% (95% CI, 6.5%-9.8%), and 8.2% (95% CI, 5.2%-12.7%), respectively. On multivariable analysis, both undertreatment and overtreatment of high-risk patients were associated with significant increases in stroke rates (odds ratio [OR]=2.32; 95% CI, 1.30-3.14; P=.005 and OR=2.28; 95% CI, 1.12-4.63; P=.02, respectively). Undertreatment was also associated with a significant increase in all-cause mortality (OR=1.59; 95% CI, 1.14-2.21; P=.006).
CONCLUSION: Only half of all eligible patients with AF are prescribed oral anticoagulation in accordance with guideline recommendations. Guideline-adherent ATT significantly reduces the risk of stroke and improves survival.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28778255     DOI: 10.1016/j.mayocp.2017.05.023

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  11 in total

1.  Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.

Authors:  Ahsan A Khan; Gregory Y H Lip
Journal:  Ann Transl Med       Date:  2017-12

2.  Prescribing of anticoagulation for atrial fibrillation in primary care.

Authors:  Kathryn A Martinez; Mark H Eckman; Matthew A Pappas; Michael B Rothberg
Journal:  J Thromb Thrombolysis       Date:  2022-04-21       Impact factor: 2.300

Review 3.  Stroke prevention strategies in high-risk patients with atrial fibrillation.

Authors:  Agnieszka Kotalczyk; Michał Mazurek; Zbigniew Kalarus; Tatjana S Potpara; Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2020-10-27       Impact factor: 32.419

4.  Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis.

Authors:  Jing-Xiu Li; Yang Li; Shu-Jun Yan; Bai-He Han; Zhao-Yan Song; Wei Song; Shi-Hao Liu; Ji-Wei Guo; Shuo Yin; Ye-Ping Chen; De-Jun Xia; Xin Li; Xue-Qi Li; En-Ze Jin
Journal:  Biomed Rep       Date:  2017-12-29

Review 5.  2018 Korean Guideline of Atrial Fibrillation Management.

Authors:  Boyoung Joung; Jung Myung Lee; Ki Hong Lee; Tae Hoon Kim; Eue Keun Choi; Woo Hyun Lim; Ki Woon Kang; Jaemin Shim; Hong Euy Lim; Junbeom Park; So Ryoung Lee; Young Soo Lee; Jin Bae Kim
Journal:  Korean Circ J       Date:  2018-12       Impact factor: 3.243

6.  Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry.

Authors:  Irene Escudero-Martinez; Michael Mazya; Christine Teutsch; Norbert Lesko; Zuzana Gdovinova; Leonardo Barbarini; Waldemar Fryze; Michal Karlinski; Adam Kobayashi; Georgi Krastev; Ana Paiva Nunes; Katarina Pasztoova; André Peeters; Piotr Sobolewski; Aleksandras Vilionskis; Danilo Toni; Niaz Ahmed
Journal:  BMJ Open       Date:  2020-05-19       Impact factor: 2.692

7.  Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial.

Authors:  Mu Chen; Qunshan Wang; Jian Sun; Peng-Pai Zhang; Wei Li; Bin-Feng Mo; Tai-Zhong Chen; Xiaoli Tang; Yi-Gang Li
Journal:  BMJ Open       Date:  2021-03-15       Impact factor: 2.692

8.  Non-adherence to Thromboprophylaxis Guidelines in Atrial Fibrillation: A Narrative Review of the Extent of and Factors in Guideline Non-adherence.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra Salter; Leanne Chalmers; Luke Bereznicki; Kenneth Lee
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

9.  Evaluating Physician Adherence to Antithrombotic Recommendations in Patients with Atrial Fibrillation: A Pathway to Better Medical Education.

Authors:  Ştefan Cristian Vesa; Sonia Irina Vlaicu; Octavia Sabin; Vitalie Văcăraș; Sorin Crișan; Sabina Istratoaie; Fatuma Samantar; Daciana Elena Popa; Antonia Eugenia Macarie; Anca Dana Buzoianu
Journal:  Int J Environ Res Public Health       Date:  2020-06-04       Impact factor: 3.390

10.  Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey.

Authors:  Monika Kozieł; Stefan Simovic; Nikola Pavlovic; Milan Nedeljkovic; Vilma Paparisto; Ljilja Music; Evgenii Goshev; Anca Rodica Dan; Sime Manola; Zumreta Kusljugic; Elina Trendafilova; Dobromir Dobrev; Gheorghe-Andrei Dan; Gregory Y H Lip; Tatjana S Potpara
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.